NCT06323356

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Conditions

• Generalized Pustular Psoriasis
• Erythrodermic Psoriasis

Interventions

Type	Name	Description
DRUG	TAK-279	Specified drug on specified days.

Timeline

• Start date: 2024-03-19
• Primary completion: 2025-10-15
• Completion: 2026-07-22
• First posted: 2024-03-21
• Last updated: 2025-11-17

Locations

20 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study